Validation of Combined PET-MR Quantitative Parameters for Cardiac Applications
Sponsor: University of California, San Francisco
Terminated
Lack of funding to continue.
Other terminated trials from University of California, San Francisco
- Hypertension · Phase PHASE2 · Jan 2026
- Menstrual Irregularity · Phase PHASE4 · Sep 2025
- Diabetes Mellitus, Type 2 · Phase NA · Feb 2025
- Asthma · Phase PHASE4 · Feb 2025
- Stone, Kidney · Phase NA · Dec 2024
See all terminations from University of California, San Francisco
Other Cardiac Disease trials with similar outcome
This NA trial investigates Cardiac Disease and is currently terminated or withdrawn. University of California, San Francisco leads this study, which shows 9 recorded versions since 2016 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2023 — Jul 2024 [monthly]
Terminated NA
-
Dec 2022 — Jan 2023 [monthly]
Terminated NA
-
Sep 2021 — Dec 2022 [monthly]
Terminated NA
Status: Unknown Status → Terminated
▶ Show 4 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Unknown Status NA
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status NA
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status NA
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status NA
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of California, San Francisco
For direct contact, visit the study record on ClinicalTrials.gov .